News and Announcements
Giles Gunesekera of Global Impact Initiative
- Published December 06, 2022 11:14PM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Global Impact Initiative (GII) creates impact investments seeking both a positive financial return and a positive social impact for its clients and stakeholders. The business works with sovereign wealth funds, central banks, insurance companies, corporations, pension plans, endowments, foundations, family offices, private banks and retail investors to create bespoke investment solutions in partnership with some of the world’s largest and most successful organisations.
Learn about the Gender Equality Fund with CEO Giles Gunesekera and GII’s other investment opportunities through this interview.
Executive Interviews
12.25% Total Returns? This Trust’s Fuel and Convenience Strategy Is Pumping Up Profits
The Queensland Property Strategy Turning Heads—And Profits In the world of commercial property investment, finding the next big opportunity is like striking gold. And right now, there’s a gold rush happening in Queensland, with Amplify, a Queensland-based Funds Manager, leading the charge. Let’s cut through the noise and see what’s really going on. The Amplify […]
A Nation Divided: Insights from Our Subscriber Poll on the Upcoming U.S. Election
October 20, 2024 This entire post was created by ChatGPT o1 utilising the data and comments from the poll. The world watches closely as the United States stands on the brink of a consequential presidential election. The outcome will shape America’s future and have profound implications for the global economy and international relations. To capture […]
A New Era of Investment in Australia’s Life Science Sector
In just six months, four new investment funds have emerged, all targeting Australia’s life sciences and healthcare companies. With scientific advancements, government backing, and structural undervaluation, these funds represent a significant moment for the sector—offering investors a rare opportunity to capitalise on growth in biotech and medtech.
Backed By Leading Investment Groups and Family Offices
